The anti-atherogenic effects of thiazolidinediones.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Diabetes Reviews

• Publication date

  2007-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/157339907779802058PMID 18220657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cited by this paper
• Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

  2006cited by this paper
• Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK.

  2006cited by this paper
• Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-compa

  2006cited by this paper
• Acute Pulmonary Edema Due to Rosiglitazone Use in a Patient With Diabetes Mellitus

  2006cited by this paper
• Peroxisome Proliferator–Activated Receptor &ggr; Regulates Angiotensin II–Stimulated Phosphatidylinositol 3-Kinase and Mitogen-Activated Protein Kinase in Blood Vessels In Vivo

  2006cited by this paper
• Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

  2006cited by this paper
• The utility of oral diabetes medications in type 2 diabetes of the young.

  2005cited by this paper
• Endothelial inflammation in insulin resistance.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005influential reference
• Insulin and insulin resistance.

  2005cited by this paper
• Rosiglitazone Protects Against Cyclosporine‐Induced Pancreatic and Renal Injury in Rats

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Thiazolidinediones and inflammation

  2005cited by this paper
• Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients.

  2005cited by this paper
• Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non‐diabetic renal diseases

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• PPAR-gamma-agonists' renal effects.

  2005cited by this paper
• Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.

  2004cited by this paper
• Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance

  2004cited by this paper
• Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.

  2004cited by this paper
• Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.

  2004cited by this paper
• Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes*

  2004cited by this paper
• Thiazolidinedione-associated congestive heart failure and pulmonary edema.

  2004cited by this paper
• Oral antidiabetic agents: 2004.

  2004cited by this paper
• Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.

  2004cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

  2003cited by this paper
• Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.

  2003influential reference
• Rosiglitazone reduces urinary albumin excretion in type II diabetes

  2003cited by this paper
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat Model

  2003cited by this paper
• Thiazolidinedione-associated congestive heart failure and pulmonary edema.

  2003influential reference
• Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.

  2003cited by this paper
• Management of Rosiglitazone-Induced Edema: Two Case Reports and a Review of the Literature

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002influential reference
• A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.

  2002cited by this paper
• Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone

  2002cited by this paper
• Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.

  2002cited by this paper
• High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells.

  2002influential reference
• Antiinflammatory and Antiarteriosclerotic Effects of Pioglitazone

  2002cited by this paper
• Large artery stiffness predicts ischemic threshold in patients with coronary artery disease.

  2002cited by this paper
• Nonhypoglycemic effects of thiazolidinediones.

  2001influential reference
• Endothelial Cell Dysfunction Leading to Diabetic Nephropathy: Focus on Nitric Oxide

  2001cited by this paper
• Thiazolidinediones for type 2 diabetes

  2001cited by this paper
• Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.

  2001cited by this paper
• Nonhypoglycemic Effects of Thiazolidinediones

  2001cited by this paper
• Diabetes mellitus: a hypercoagulable state.

  2001cited by this paper
• A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus.

  2001cited by this paper
• A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.

  2001cited by this paper
• Roles of PPARs in health and disease

  2000cited by this paper
• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  2000cited by this paper
• Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

  2000cited by this paper
• Hepatic Failure in a Patient Taking Rosiglitazone

  2000cited by this paper
• PPAR agonists as direct modulators of the vessel wall in cardiovascular disease

  2000cited by this paper
• Peroxisome proliferator‐activated receptors in the cardiovascular system

  2000cited by this paper
• Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.

  1999cited by this paper
• Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

  1999cited by this paper
• Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

  1999cited by this paper
• Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells.

  1999cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• THIAZOLIDINEDIONES: TOOLS FOR THE RESEARCH OF METABOLIC SYNDROME X

  1998cited by this paper
• Relation between coronary artery disease, aortic stiffness, and left ventricular structure in a population sample.

  1998cited by this paper
• Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells.

  1997cited by this paper
• Troglitazone Reduces Contraction by Inhibition of Vascular Smooth Muscle Cell Ca2+ Currents and Not Endothelial Nitric Oxide Production

  1997cited by this paper
• Diagnosis and Management of Type 2 Diabetes

  1997cited by this paper
• Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats.

  1997cited by this paper
• Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications.

  1996cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women.

  1995cited by this paper
• Impaired endothelium‐dependent relaxation in isolated resistance arteries of spontaneously diabetic rats

  1995cited by this paper
• Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Atherosclerosis Risk in Communities Study.

  1995cited by this paper
• Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat

  1994cited by this paper
• The pathogenesis of atherosclerosis: a perspective for the 1990s

  1993cited by this paper
• Aortic distensibility and left ventricular structure and function in isolated systolic hypertension.

  1993cited by this paper
• Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus

  1992cited by this paper
• Bioassay of endothelium-derived relaxing factor in diabetic rat aorta.

  1992cited by this paper
• Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women.

  1992cited by this paper
• Attenuation of endothelium-dependent relaxation in aorta from diabetic rats.

  1986cited by this paper
• Estimation of total arterial compliance: an improved method and evaluation of current methods.

  1986cited by this paper
• Oral Antidiabetic Agents

  1959cited by this paper

• The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction

  2023cites this paper
• Diabetic Nephropathy and Gaseous Modulators

  2023cites this paper
• Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance

  2022cites this paper
• A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis

  2022cites this paper
• A review of the anti‐inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes

  2018cites this paper
• PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.

  2017cites this paper
• Effects of peroxisome proliferator activated receptor-gamma 2 gene Pro12Ala polymorphism on fasting blood lipids: a meta-analysis.

  2011cites this paper
• Chlamydia pneumoniae induces macrophage-derived foam cell formation by up-regulating acyl-coenzyme A: cholesterol acyltransferase 1.

  2009cites this paper
• Adipose inflammation: cause or consequence of obesity-related insulin resistance

  2008cites this paper
• The prince and the pauper. A tale of anticancer targeted agents

  2008cites this paper